SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer

The purpose of the Phase 1 research is to test the safety, tolerability, maximum tolerated dose, and pharmacokinetics (PK- the study of how a medicine moves through subject body. It looks at how the drug is absorbed, travels in your blood, reaches different parts of subject body, and is eventually broken down and removed) of the SNB-101.The Phase 2 is to determine the optimal dose (amount of medicine that works best to treat a condition while causing the fewest side effects) of SNB-101 for further research and to collect a further information on PK, safety and tolerability. Once subject has c

Trial Details

NCT ID
NCT07391813
Phase
PHASE1 / PHASE2
Sponsor
SN BioScience
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SNB-101
Locations (sample)
  • Kamenitz, Serbia|45.22334,19.84263

Key Eligibility Criteria

  • Male or female patients over 18 years of age.
  • Male or fertile female patients who have agreed to comply with effective contraceptive methods as required by this protocol and the specified contr…
  • Participants must have a cytologically or histologically confirmed small cell lung cancer which is locally advanced or metastatic and has progresse…
  • Have measurable or evaluable disease consistent with RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →